Wegovy coupons & savings
semaglutide · manufacturer programs, telehealth bundles, discount cards
Jump to section
Wegovy's list price is approximately $1,349/month at retail pharmacies. The fastest path to lower out-of-pocket cost depends on whether you have insurance and whether your plan covers Wegovy for weight management.
Your options
- RecommendedManufacturer
NovoCare Self-Pay
$349/monthEligibility: No insurance required; filled through NovoCare Pharmacy. New patients pay $199/month for the first 2 fills of 0.25 mg and 0.5 mg (through December 31, 2026). Wegovy HD 7.2 mg is $399/month; the Wegovy pill is $149-$299/month by dose. Government-insured patients may pay the self-pay price outside their insurance.
- Telehealth
Ro Body program
from $145/month (program fee, Rx separate)Eligibility: Clinical intake + state availability. Branded GLP-1 prescriptions routed via insurance or direct-pay; medication cost is separate from the program fee.
⚠ Compounded semaglutide is no longer routinely available after the shortage resolution — pricing reflects the branded pathway.
- Telehealth
Noom Med
from $179/monthEligibility: BMI ≥27 with comorbidity OR BMI ≥30. Includes behavioral coaching + GLP-1 access.
- Discount card
GoodRx coupon
~$1,320/monthEligibility: No eligibility restrictions. Modest discount on branded Wegovy at retail pharmacies.
⚠ Wegovy list price doesn't have meaningful discount-card savings. NovoCare or telehealth are the real price levers.
Important notes
- Insurance is the cheapest path when available — confirm with your specific plan's formulary first.
- Manufacturer self-pay programs (NovoCare) cannot be combined with insurance copay assistance.
- Eligibility for NovoCare can change; check current terms before relying on quoted prices.
What Wegovy actually costs you: the four scenarios
Wegovy's roughly $1,349/month list price is a starting point almost no one pays. Which of four situations you are in decides your real cost and which program to chase first.
Scenario 1 — commercial insurance that covers Wegovy for weight management: your plan's copay applies, often further reduced by a manufacturer copay-savings offer for covered commercial patients. This is usually the lowest path, but many employer plans specifically exclude weight-loss drugs, so 'I have insurance' does not guarantee coverage.
Scenario 2 — insurance that excludes weight-loss drugs: the copay card does not help because there is no covered claim to apply it to. Your realistic levers are NovoCare self-pay ($349/month) or a telehealth bundle, after first trying an appeal — especially now that semaglutide's cardiovascular indication can unlock coverage a weight-only prescription cannot.
Scenario 3 — no insurance: NovoCare self-pay at $349/month is the manufacturer's cash price and typically the cheapest legal branded route. Scenario 4 — Medicare or Medicaid: the copay card excludes you, but NovoCare lets government-insured patients pay the self-pay price outside their insurance, and Medicare Part D enrollees may qualify for the Medicare GLP-1 Bridge ($50/month from July 1, 2026 through December 31, 2027). Beyond that, coverage hinges on your plan and any qualifying medical indication (such as cardiovascular risk reduction).
Why discount cards barely move Wegovy's price
For many drugs, a GoodRx or SingleCare card is the easy win. Wegovy is an exception: as a high-list-price branded drug with no generic, discount-card prices stay close to retail (often still well over $1,000). The card is not the lever here.
The real levers are the manufacturer channel (NovoCare self-pay or the commercial copay card) and telehealth bundles that price the medication plus a program fee. If someone points you to a discount card as the Wegovy 'savings hack,' they are pointing at the weakest option — check NovoCare and coverage first.
NovoCare self-pay: the eligibility fine print
The NovoCare self-pay price is aimed at patients without insurance, or with insurance that does not cover Wegovy — not as a top-up for people who already have coverage. It also cannot be combined with insurance copay assistance; you are in one lane or the other. Patients with Medicare, Medicaid, or other government coverage cannot use the copay card, but NovoCare states they may pay the self-pay price if the fill is processed outside their insurance.
Program terms and the exact price change periodically, so confirm the current figure and eligibility rules on NovoCare directly before you build a budget around it. The number quoted today is a guide, not a locked-in guarantee.
Getting the lowest price: the decision order
Confirm first whether your commercial plan covers Wegovy for weight management — if yes, the copay (plus any manufacturer copay offer) usually wins. If it is excluded, file a formulary-exception appeal, leaning on any qualifying condition such as established cardiovascular disease. Only if coverage is genuinely unavailable should you compare NovoCare self-pay against telehealth bundles on total monthly cost. Paying full retail is the outcome to avoid; every path above beats it.
Charity and manufacturer assistance: what is actually open
Status read on each program’s own site on September 16, 2026
3 of the 10 programs below were closed to new applicants on that date, including every charity fund that pays toward a weight-loss GLP-1. We have no relationship with any of them and cannot influence an application. Fund status changes without notice, so confirm on the program’s own page before you count on it.
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Obesity fund
The catch: This is the one charity fund built for weight-loss drugs, and it is closed. Its own rules also require health insurance that already covers the expense, so a cash-pay patient would not qualify even when it is open.
- Income limit as stated
- Have an income at or less than 300% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have health insurance that covers your qualifying expenses (fund list row: “Health insurance (any)”)
- Award
- $1,000 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Type 2 diabetes (T2DM) fund
The catch: Closed, and it was never open to everyone: this fund requires government-insured coverage, so commercially insured and uninsured patients are ineligible. The companion type 2 diabetes health equity fund is closed as well.
- Income limit as stated
- Have an income at or less than 500% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have government-insured coverage that covers your qualifying expenses (fund list row: “Government-insured coverage (Medicare, Medicaid, or TRICARE)”)
- Award
- $1,500 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
TotalAssist (program-level rules)
Program-wide eligibility (nearly 150 funds)
The catch: The program runs, but you can only apply to a fund that is open, and both funds that reach GLP-1s — obesity and type 2 diabetes — were closed on the date checked. A closed fund offers a notification sign-up, not a waitlist queue.
- Income limit as stated
- Have a household income of 500% or less than the Federal Poverty Level (FPL) guidelines, adjusted by the Cost-of-Living Index (COLI) for where the patient lives — with the exception: “Household income of 300% or less than the Federal Poverty Level (only our obesity fund)”
- Insurance requirement
- Have active insurance coverage that includes coverage for pharmaceutical products; the required insurance type varies by fund
- Award
- Varies by fund; grants run on an “individual 12-month rolling grant cycle”
- Phone
- 866-512-3861
Status checked: Open on September 16, 2026. Source
- Closed
HealthWell Foundation
Type 2 Diabetes fund
The catch: HealthWell has no obesity or weight-management fund at all, so a weight-loss prescription has no route here. The type 2 diabetes fund is the only one that reaches a GLP-1, and it is closed: “This fund is temporarily closed to new patients due to lack of sufficient funding.”
- Income limit as stated
- 300–500% of the Federal Poverty Level (fund page); program-wide, “up to 400 or 500 percent of the Federal Poverty Level (somewhat more in cities where the cost of living is higher)”
- Insurance requirement
- “some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment”; “Drug discount cards do not qualify as insurance.”
- Award
- $1,000 per patient, grant period 12 months
- Phone
- (800) 675-8416 (Mon–Fri 9am–5pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
Novo Nordisk Patient Assistance Program (PAP)
Manufacturer patient assistance program (free medicine)
The catch: Ozempic is the only GLP-1 on the product list. Wegovy and Saxenda are not on it, so there is no free-medicine route to a branded obesity GLP-1 from Novo Nordisk. For Ozempic the program takes uninsured patients only, at or below 200% of the federal poverty level.
- Income limit as stated
- Ozempic (uninsured): “Total household income must be at or below 200% of the federal poverty level”; insulins and all other products: “Total household income must be at or below 400% of the federal poverty level”
- Insurance requirement
- Must have Medicare or no insurance; private or commercial insurance makes a patient ineligible. For Ozempic, uninsured patients only — Medicare Part D patients are no longer eligible for Ozempic through PAP.
- Award
- Medicine at no cost; approval lasts 12 months for uninsured patients, through the end of the calendar year for Medicare patients
- Phone
- 1-866-310-7549 (Mon–Fri 8am–8pm ET)
Status checked: Open on September 16, 2026. Source
- Open
Lilly Cares Foundation
Lilly Cares Patient Assistance Program
The catch: The only GLP-1 offered is Trulicity, a type 2 diabetes drug. Zepbound and Mounjaro appear in no medication group and on no Available Medications page, so tirzepatide has no free-medicine route here. Private commercial insurance disqualifies.
- Income limit as stated
- Group 1 Medications (at or below 300% FPL); Group 2 Medications (at or below 400% FPL); Group 3 & Group 4 Medications (at or below 500% FPL) — 2026 FPL guidelines. Household of 1/2/3/4 for Group 1: $47,880 / $64,920 / $81,960 / $99,000.
- Insurance requirement
- For Group 1, 2 and 3 medications, which includes Trulicity: “1) You have no insurance, or 2) you have Medicare Part D (not applicable to infused medications), or 3) you have Medicare Part B but have no supplemental or secondary insurance”
- Award
- Free medication; enrollment generally lasts 12 months or to the end of the enrollment period
- Phone
- 1-800-545-6962
Status checked: Open on September 16, 2026. Source
- Open
Patient Advocate Foundation
Case Management Services & MedCareLine; Financial Aid Funds
The catch: Case management is advocacy, not money: it does not pay for medication. It is worth a call for an insurance denial or appeal. The grant arm is TotalAssist, whose obesity and type 2 diabetes funds are closed.
- Income limit as stated
- No income threshold is published for case management; TotalAssist income limits apply to grants
- Insurance requirement
- No insurance requirement is stated for advocacy; case management is offered to patients “facing a chronic, life-threatening or debilitating diagnosis”
- Award
- Case management carries no grant; TotalAssist grants vary by fund
- Phone
- Case Management (800) 532-5274 (Mon–Fri 8:30am–5pm ET); TotalAssist (866) 512-3861; Financial Aid Funds (855) 824-7941
Status checked: Open on September 16, 2026. Source
- Directory only
NeedyMeds
Information directory and free drug discount card
The catch: NeedyMeds awards no money. It lists other people's programs and issues a discount card — and a discount card is not insurance, which matters because HealthWell states “Drug discount cards do not qualify as insurance.” for its own eligibility.
- Income limit as stated
- None for the discount card: “Can be used by anyone — no financial, age, or residency restrictions”
- Insurance requirement
- None; the card is usable with or without insurance
- Award
- No grant. The card is advertised as “Save up to 80%” on prescriptions.
- Phone
- 800-503-6897 (toll-free helpline)
Status checked: Directory only on September 16, 2026. Source
- Directory only
RxAssist
Directory of patient assistance programs
The catch: A lookup tool, not a funder: no money, no grants, no application, and no patient helpline published on the site. Use it to find manufacturer programs, not to pay for a prescription.
- Income limit as stated
- None — RxAssist awards nothing; income rules belong to the programs it lists
- Insurance requirement
- None stated
- Award
- No award; directory only
- Phone
- No patient helpline published on the site
Status checked: Directory only on September 16, 2026. Source
- Open
AZ&Me Prescription Savings Program (AstraZeneca)
Manufacturer patient assistance program
The catch: No GLP-1 for obesity is offered by this program, and its two diabetes drugs stopped taking new patients: “Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR”. Any commercial insurance disqualifies.
- Income limit as stated
- Annual adjusted gross income must be at or below 300% of the Federal Poverty Level (FPL) for Primary and Specialty Medications; 500% of FPL for Rare Disease Medications
- Insurance requirement
- “Not have any commercial (private or employer-sponsored) insurance or government insurance other than Medicare”
- Award
- Medication at no cost, up to a 90-day supply per fill
- Phone
- 1-800-292-6363 (Mon–Fri 9:00am–6:00pm ET)
Status checked: Open on September 16, 2026. Source
Manufacturer copay cards. The Zepbound, Mounjaro, Wegovy and Ozempic savings cards all exclude patients in a government program. The Wegovy terms put it plainly: “Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, VA, DOD, TRICARE, or any similar federal or state health care program”. If you are on Medicare or Medicaid, the $25 card price is not available to you, whatever the ad says.
Compounded GLP-1s. No program reviewed covers compounded semaglutide or tirzepatide. TotalAssist limits approved medications to products that are “FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines”. Manufacturer programs supply only their own branded products.
Telehealth prescriptions. No program reviewed publishes a telehealth exclusion on its own site. Where a prescription was written is not something these programs ask about in their published rules.
More on Wegovy
Frequently asked
What's the cheapest way to get Wegovy?+
Based on the programs currently tracked, the lowest sticker price for Wegovy is "Ro Body program" at from $145/month (program fee, Rx separate). Eligibility varies by program — check the requirements for each option above before counting on a price.
Does insurance cover Wegovy?+
Insurance coverage for Wegovy depends on the plan and indication. Many commercial plans cover semaglutide for FDA-approved uses with prior authorization; off-label use is rarely covered. Check your formulary or run your plan through our insurance coverage tool.
Are coupons for Wegovy legitimate?+
Manufacturer programs from Wegovy's maker and federally registered patient assistance foundations are legitimate. Be cautious with discount cards that promise prices far below retail without verifying the dispensing pharmacy is licensed in your state.
What's the best option for Wegovy right now?+
Editorial pick: NovoCare Self-Pay at $349/month. No insurance required; filled through NovoCare Pharmacy. New patients pay $199/month for the first 2 fills of 0.25 mg and 0.5 mg (through December 31, 2026). Wegovy HD 7.2 mg is $399/month; the Wegovy pill is $149-$299/month by dose. Government-insured patients may pay the self-pay price outside their insurance. This is a starting point; your situation may favor a different program based on insurance and clinical eligibility.